Skip to Content

PFS of 63% after 5 years for patients with multiple myeloma patients in maintenance therapy with lenalidomide and dexamethasone

In this MEDtalk Laura Rosiñol, MD,Hematology Department, Hospital Clínic, Barcelona, Spain member of the PETHEMA-GEM, presents data for the potential benefit of postransplant maintenance therapy with Ixazomib/lenalidomide/dexamethasone as opposed to lenalidomide/dexamethasone alone.

Laura Rosinol

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top